Annals of Pediatric Cardiology
About us | Current Issue | Archives | Ahead of Print | Instructions | Submission | Subscribe | Advertise | Contact | Login 


    Advanced search

    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Email Alert *
    Add to My List *
* Registration required (free)  

    Article Figures
    Article Tables

 Article Access Statistics
    PDF Downloaded80    
    Comments [Add]    

Recommend this journal


Table of Contents   
Year : 2021  |  Volume : 14  |  Issue : 3  |  Page : 302-309
Early multicenter experience of Melody valve implantation in India

1 Department of Pediatric Cardiology, Sir H N Reliance Foundation Hospital, Mumbai, Maharashtra, India
2 Department of Pediatric Cardiology, Fortis Escorts Heart Institute, New Delhi, India
3 Department of Pediatric Cardiology, Madras Medical Mission, Chennai, Tamil Nadu, India
4 Department of Pediatric Cardiology, Frontier Lifeline Hospital, Chennai, Tamil Nadu, India

Click here for correspondence address and email

Date of Submission21-Apr-2021
Date of Decision26-May-2021
Date of Acceptance28-May-2021
Date of Web Publication26-Aug-2021


Background : Transcatheter valves provide a safe and effective alternative to surgery for treating dysfunctional right ventricular outflow tracts (RVOTs). We present our early multicenter experience of percutaneous pulmonary valve implantation (PPVI) using Melody valve (Medtronic Inc., Minneapolis, MN).
Methods : Patients with stenosed conduits or degenerated bioprosthetic valves in RVOT with combined stenosis and regurgitation were evaluated for suitability of Melody valve implantation. After undergoing an initial structured training, PPVI using Melody transcatheter pulmonary valve (TPV) was guided by an approved proctor. Conduits were serially dilated and prestented with careful coronary interrogation, and bioprosthetic valves were dilated with high-pressure balloons. Clinical and echocardiographic follow-up was performed at 6 monthly intervals.
Results : Fifteen patients (three females) aged 23.1 ± 9.5 years in NYHA Class II-III underwent Melody TPV implantation in four Indian centers. The underlying anatomy comprised surgically implanted bioprosthetic valves for pulmonary regurgitation (n= 5), conduit repair for pulmonary atresia (n = 4), Rastelli repair (n = 3), truncus (n = 1), and Ross procedure (n = 2). Twelve patients had more than one previous surgery. Doppler gradient decreased from 74.2 ± 21.5 mmHg to 10.2 ± 4.5 mmHg after the PPVI. At a median follow-up of 14 months (1–39 months), all the patients were in NYHA Class I with echocardiographic gradients of 8 ± 5.7 mmHg with no evidence of pulmonary regurgitation. There were no major procedural adverse events or deaths.
Conclusions : Our early experience shows encouraging results of the PPVI program in India with proctored case selection and meticulous planning. It also confirms the safety and efficacy of Melody TPV for treating dysfunctional RVOT in postoperative patients.

Keywords: Early outcomes, learning curve, transcatheter pulmonary valve replacement

How to cite this article:
Sheth K, Azad S, Dalvi B, Parekh M, Sagar P, Anantharaman R, Radhakrishnan S, Sivakumar K. Early multicenter experience of Melody valve implantation in India. Ann Pediatr Card 2021;14:302-9

How to cite this URL:
Sheth K, Azad S, Dalvi B, Parekh M, Sagar P, Anantharaman R, Radhakrishnan S, Sivakumar K. Early multicenter experience of Melody valve implantation in India. Ann Pediatr Card [serial online] 2021 [cited 2022 Jan 27];14:302-9. Available from:

   Introduction Top

Long-term durability of surgical intervention on the right ventricular outflow tract (RVOT) for different congenital heart diseases (CHD) is highly variable, with allograft or bioprosthetic valves becoming dysfunctional and requiring further intervention over time.[1] Percutaneous pulmonary valve implantation (PPVI) with the Melody transcatheter pulmonary valve (TPV) (Medtronic Inc., Minneapolis, MN) has shown good hemodynamic and clinical outcomes in the treatment of these patients.[2],[3] Numerous trial and registry data have demonstrated reduced RVOT gradients, elimination of pulmonary regurgitation, and improved symptomatic status after implantation.[4],[5],[6],[7],[8] Despite its introduction for clinical use in the year 2000 and worldwide experience of over 15,000 global implants, resource-limited settings in India and complex import processes delayed its clinical utility till recently. We present the short-term clinical and hemodynamic outcomes after TPVI with the Melody valve in Indian institutions.

   Methods Top

Patient selection

Patients with CHD operated with the use of allograft conduits or bioprosthetic valves for reconstruction of RVOT were clinically monitored and evaluated by echocardiography. Worsening of symptoms due to RVOT dysfunction, right ventricular systolic pressure exceeding two-thirds of systemic pressure, peak RVOT gradient exceeding 80 mmHg on Doppler, severe pulmonary regurgitation and right ventricular dysfunction with ejection fraction below 47% were considered as indications for PPVI.[9],[10],[11],[12] These patients were subjected to a comprehensive contrast-enhanced computed tomography (CECT) for delineating the RVOT and pulmonary artery anatomy, relationship of coronary arteries to the conduit [Figure 1], and measuring the conduit dimensions. Cardiac magnetic resonance imaging (MRI) was done in selected patients who had predominant pulmonary regurgitation and dilated dysfunctional right ventricle. Details of the size and model of bioprosthetic valve were reviewed to obtain information about their true internal diameter before a valve-in-valve implantation.[13] Hemodynamically significant branch pulmonary artery stenosis with documented perfusion anomaly was addressed by stent angioplasty or high-pressure balloons before PPVI [Figure 2].
Figure 1: Coronary artery relation to conduit. Multiplanar reformatted computed tomographic image (a) demonstrates the distal part of the calcified conduit (C) overlying the right coronary artery origin from aorta. Another patient after Ross surgery (b) with a calcified conduit (c) which is in close relation to both the coronary artery origins (black arrows) from a dilated aortic root. PA: Pulmonary artery, LPA: Left pulmonary artery, RVOT: Right ventricular outflow tract, SVC: Superior vena cava, RPA: Right pulmonary artery

Click here to view
Figure 2: Distal branch pulmonary artery stenosis. Axial computedtomographic image of a patient with a degenerated bioprosthetic valve (a) implanted for pulmonary regurgitation after truncus repair with absent left pulmonary artery shows stenosis between the pulmonary trunk and the lone right pulmonary artery. A second patient (b) after initial left modified Blalock–Taussig shunt followed by conduit repair for tetralogy has stenosis of origin of left pulmonary artery near the shunt insertion. PA: Pulmonary artery, LPA: Left pulmonary artery, SVC: Superior vena cava, RPA: Right pulmonary artery

Click here to view

Initiating a melody program in India

Implanting physicians were initially given off-site training with didactic lectures on case selection based on analysis of three-dimensional imaging, device preparation, and device implantation. This was followed by step-by-step observation of Melody valve implantation. Patients were evaluated in the respective institutions with special emphasis on planning the procedure with CECT which was shared with the proctor for confirming the indication, assessing the suitability for PPVI in terms of the coronary anatomy and extent of calcifications, and also acquiring the necessary hardware required for the procedure. This was extremely important in the resource-limited environment due to limited shelf inventory. Being a more expensive alternative to surgery, there was an additional challenge in arranging the finances for the procedure.

Initial steps

Standard protocol after obtaining detailed informed consent from patients included preadmission screening for dental, skin and other infections, periprocedural intravenous antibiotics for 24 h, general anesthesia, heparinization to maintain activated clotting time more than 250 s, acquisition of hemodynamic data, RVOT angiography in right anterior oblique, lateral and cranial projections to define its dimensions, and branch pulmonary artery anatomy. Following this, coronary artery interrogation was done with simultaneous coronary angiography and inflation of a compliant Amplatzer sizing balloon (Abbott, Plymouth, MN) or a semicompliant Z-med balloon (NuMED corporation, Cornwall, ON). In case of a severely calcific conduit, coronary arteries were interrogated only after partial deployment of the covered stent, which was gradually dilated with repeated coronary injections to assess their proximity to the conduit [Figure 3]. In pliable conduits with minimal calcification, serial balloon interrogation was performed using progressively larger balloons having a diameter of 18–22 mm [Figure 4].
Figure 3: Strategy in densely calcified conduit. Calcified conduits at risk of rupture are initially interrogated with compliant sizing balloons during coronary injection (a) before prestenting of the conduit with a covered stent. This covered stent is later expanded to larger diameter of 20 mm (b) with high-pressure balloons. Once the conduit gradient is eliminated, Melody valve is positioned in the landing zone present (c) and expanded. A competent pulmonary valve is shown in pulmonary arteriogram recorded in lateral view (d). PA: Pulmonary artery, LPA: Left pulmonary artery, LCA: Left coronary artery

Click here to view
Figure 4: Balloon interrogation of coronary arteries. Left coronary artery origin and its left anterior descending and circumflex (Cx) branches are demonstrated in caudal projection (a) before balloon interrogation of the conduit. Inflation of a 20 mm balloon (b) in the conduit does not cause any compression of the left coronary artery. Even though a left coronary angiogram in a lateral projection (c) after inflation of a larger 22 mm balloon fails to show the coronary ostium, the caudal projection (d) shows that the shift of calcium in the postero-inferior wall of the conduit causes extrinsic left coronary artery compression

Click here to view

Creation of landing zone

To prepare a landing zone, a long 14Fr sheath was tracked over a 0.035” Lunderquist wire (Cook Medical, Bloomington, USA). A 0.035” E-wire (Jotec, GmbH, Hechingen, Germany) was used occasionally for additional support. The landing zone was prepared using 8-zig CP stent (NuMED, Hopkinton, NY) or AndraStent XL (AndraMed, GmbH, Reutlingen, Germany) mounted on Z-med or BIB balloon (NuMED, Hopkinton, NY). Covered stents were preferred in densely calcified conduits at a risk of rupture. Size and length of the stent used were decided based on CECT data, which was confirmed with angiographic measurements. Angiographic assessment was done to confirm the integrity of the conduit after the stent placement. While residual gradients (>10 mmHg) were addressed by postdilation using 20/22 mm  Atlas More Details Gold PTA balloon (Bard Peripheral Vascular, Tempe, AZ), a nonuniform stent expansion with an oval configuration visualized on a barrel-view observed on caudal projection was addressed by reinforcing additional stent. Procedural optimization was done to achieve a stent diameter of 20–22 mm with a gradient < 10 mmHg. Bioprosthetic valves were predilated with Atlas Gold PTA balloon to assess their compliance and were not routinely prestented [Figure 5].
Figure 5: Valve-in-valve implantation within bioprosthetic valves. Left coronary artery injection in lateral view (a) shows its relation to the bioprosthetic valve before its interrogation using a high pressure 22 mm balloon (b) across the valve. A Melody valve is expanded within the bioprosthetic valve, which acts as the landing zone (c). Final pulmonary arteriogram in cranial projection (d) shows absence of regurgitation

Click here to view

Melody valve implantation

An 18 mm Melody TPV was deployed using 20 or 22 mm Ensemble II system (Medtronic, Minneapolis, MN) within the landing zone or bioprosthetic valve ring.[14] Following the deployment of Melody valve, pressure gradient was recorded across the valve and pulmonary artery angiogram was done in cranial and lateral projections to identify pulmonary regurgitation. Hemostasis was obtained using ProGlide (Abbott, Plymouth, MN) or figure-of-eight suture. Postprocedural protocol included 48 h in-hospital observation, continuation of heparin for 48 h, predischarge electrocardiogram (ECG), chest X-ray, Echo-Doppler study, antiplatelet therapy with aspirin and/or clopidogrel for life, and counseling on lifelong infective endocarditis prophylaxis. Follow-up evaluation at 4 weeks, 6 months, and 1 year comprised of physical examination, ECG and Echo Doppler evaluation, and CECT in selected patients.

   Results Top

Cardiac anatomy in patients

A total of 15 patients including three females underwent Melody TPV implantation in four institutions in the past 3 years since January 2018 [Table 1]. The mean age of the patients was 23.1 ± 9.5 years and their weight ranged from 26 to 81 kg. The basic anatomy was variable and comprised degenerated bioprosthetic valves that were previously implanted for severe pulmonary regurgitation following tetralogy of Fallot (TOF) repair in four patients and truncus repair in one patient (n = 5), conduit repair for TOF with pulmonary atresia (n = 3) and TOF with absent pulmonary valve (n = 1), Rastelli repair for transposition of great arteries (n = 3), repair of truncus (n = 1), and Ross procedure (n = 2). Twelve patients had more than at least one previous cardiac surgery. Significant comorbidities included tracheoesophageal fistula repair in one patient and medical treatment for infective endocarditis many years earlier in another patient. None of the patients exhibited features of known syndromes. All patients were symptomatic with NYHA Class III in four patients and Class II in the rest. The coronary artery anatomy was favorable on CECT in all except one where there was close proximity of both coronaries to the partially calcified conduit. Being an expensive procedure, some patients were partly funded through institutional concessions, insurance, and other charities.
Table 1: Patient details

Click here to view

Hemodynamic parameters

The peak gradient across the RVOT on catheterization was 74.2 ± 21.5 mmHg in the 15 patients. The right ventricular systolic pressure was near-systemic in 11 patients, subsystemic in 2, and supra-systemic in 2 patients. While five dysfunctional RVOT was contributed by degenerating bioprosthetic valves, dysfunctional conduits in the other ten patients included four homografts and six xenografts. Cardiac MRI performed in four patients to quantify severe pulmonary regurgitation showed indexed right ventricular end-diastolic volume exceeding 160 ml in all of them. The patients had varying combinations of moderate to severe pulmonary stenosis with moderate to severe pulmonary regurgitation. Predominant regurgitant RVOT requires a different prestenting strategy as the risk of stent migration is high and larger prestents are required.

Preparation of the landing zone

Five patients with degenerated bioprosthetic valves underwent high-pressure balloon dilatation to a final diameter of 22 mm to confirm the adequacy of the landing zone without any prestents. The other ten patients with conduits were serially balloon interrogated with initial compliant balloons followed by guarded use of semi-compliant balloons depending on the expansion of the conduit. Prestenting was done with covered stent in eight patients with severely calcified conduits and uncovered stent in two other patients. Covered stents were used in all three patients with hand-fashioned pericardial conduits and they were not significantly over dilated. One patient with both coronaries arising close to the proximal end of the conduit on CECT was serially tested with progressively larger semi-compliant balloons until a 22 mm balloon showed mild external compression of the left coronary artery. As the earlier use of a 20 mm balloon did not compromise coronary flows, prestenting was done using 20 mm balloon. Interventions on pulmonary arteries were done in three patients. One patient with left pulmonary artery stenosis and documented 70:30 perfusion anomaly underwent stent angioplasty using a 22 mm AndraStent XL using a 16 mm balloon [Figure 6]. Another patient with bilateral moderate pulmonary artery stenosis underwent balloon angioplasty without stenting, as the right ventricular pressures reduced to less than half-systemic following the balloon dilatation. The third patient after conduit repair for truncus arteriosus and absent left pulmonary artery underwent a bioprosthetic valve replacement for conduit dysfunction along with pericardial patch repair of right pulmonary artery. This patient had a narrowing of the lone right pulmonary artery origin that was stented to 18 mm using a CP stent followed by deployment of Melody valve.
Figure 6: Left pulmonary artery stent followed by Melody valve. Pulmonary angiogram in caudal projection (a) demonstrates narrowing of the origin of the left pulmonary artery shown in arrow and large right pulmonary artery. After stent angioplasty of the left pulmonary artery, interrogation of the left coronary artery after inflating an 18 mm balloon in the conduit (b) demonstrates normal coronary flows. The conduit is prestented with a Cheatham platinum stent (c) followed by implantation of Melody valve (d) within the prestented landing zone

Click here to view

Melody valve implantation

Melody TPV 18 mm was chosen in all patients and deployed using 22 mm Ensemble delivery system in 9 patients and 20 mm delivery system in the rest. While 8 patients had prestenting to enlarge the conduit to 20–22 mm before Melody valve implantation, two patients had a bare-stent crimped manually over the Melody valve within the Ensemble delivery system [Figure 7] and delivered as a one-step procedure.[15] None of the five bioprosthetic valves were prestented. The valve was successfully deployed in the landing zone in all patients. The postprocedural gradient across the valve was 10.2 ± 4.5 mmHg. Pulmonary artery angiogram after valve implantation did not show any regurgitation. Hemostasis was achieved with ProGlide in five patients and manual figure-of-eight suture in the rest.
Figure 7: One-step combined prestenting and implantation of Melody valve. Right ventriculogram (a) shows a narrow dysfunctional conduit and dilated left (left pulmonary artery) and right (right pulmonary artery) pulmonary arteries after repair of tetralogy of Fallot with absent pulmonary valve syndrome. Left coronary artery interrogation with a 22 mm balloon in the conduit (b) shows unobstructed flows. A 42 mm AndraStent XL is crimped around the Melody valve within the 22 mm Ensemble delivery system (c) as an one-step procedure and positioned across the narrowed conduit. Pulmonary arteriogram after expansion of the Melody valve (d) shows absence of pulmonary regurgitation

Click here to view


There were no major complications. Four minor complications were noted. One guidewire injury to the lung parenchyma spontaneously resolved in 48 h. Brachial plexus neurapraxia was seen in one patient due to nerve stretch related to the upper limb positioning during the prolonged procedure recovered completely over the next 3 months. A small femoral arteriovenous fistula identified at 24 h was managed by ultrasound-guided compression for 30 min. One patient had fever for 4 days following the valve implantation, responded to nonsteroidal drugs suspected to be due to persistence of glutaraldehyde elution from the valve. At a median follow-up of 14 months (1–39 months), all the patients were in NYHA Class I with echocardiographic gradients of 8 ± 5.7 mmHg with no evidence of pulmonary regurgitation. One patient with bilateral balloon angioplasty of pulmonary arteries had Doppler gradients of 26 and 30 mmHg across the branch pulmonary arteries.

   Discussion Top

Managing the learning curve

There is a learning curve for every procedure, and Melody valve implantation is no exception. Detailed history with assessment of previous surgical notes was very important for planning. This helped in deciding the size of stent in preparing the landing zone. Preprocedure workup including CECT helped in deciding and acquiring the stents and balloons needed for prestenting. Unlike most other percutaneous valves that require specialized crimping tools and complex valve loading, Melody valve has simple preparatory steps that can easily be performed by the implanting clinician rather than specially trained technicians from the industry thereby minimizing the learning curve. This was clearly evident from the early experience in all the four centers. Institutional and operator experience in complex structural heart interventions plays a major role in success of these procedures.

Valve and patient selection

PPVI has become an accepted alternative to surgical conduit replacement, with low morbidity and mortality rates.[16],[17] A large experience using Melody valve has been demonstrated in various trials and registries across the globe.[4],[5],[6],[7],[8] The alternative options of Sapien S3 and straight Venus-P valve have been used only in a few patients.[18],[19] Indications for PPVI are identical to surgical indications. The essential prerequisites for Melody valve implantation include patients above 25 kg having dysfunctional conduit or bioprosthetic valve measuring >16 mm and <22 mm and favorable RVOT morphology in terms of its relation to the adjacent coronary arteries.[5],[6],[16] Contraindications consist of sepsis, active endocarditis, pregnancy, and a conduit size that is incompatible with the valve size and coronary artery running very close to the conduit at the level of the area of interest.[16],[17] All the patients in this cohort were symptomatic with severe conduit dysfunction and fulfilled the necessary prerequisites for Melody implantation.

Role of contrast-enhanced computed tomography

Computed tomography is one of the most essential investigations, providing information regarding anatomical aspect of RVOT, level, severity, and extent of calcification of RVOT and spatial relation of conduit to the coronary arteries. This information is of utmost importance in deciding the number, length and size of the stents, and requirement of balloons for deployment and postdeployment dilatation. Being an infrequently performed procedure, this planning was crucial in arranging the hardware in our resource-limited environment. Even though a likelihood of coronary artery compression was predicted on CECT, the ultimate decision was based on balloon interrogation.

Acquiring appropriate hardware before procedure

Role of appropriate long sheaths, guidewires, balloons, and stents was very crucial for the successful outcome in these procedures. With angulated outflow tract and with unpredictable lie of the calcific conduit, tracking of large 14F or 16F sheaths was challenging. Use of heavy Lunderquist or E-wires, braided sheaths, gentle manipulations using pull-push technique, and gentle rotation of the sheath-dilator assembly were needed to precisely place the prestent. A wide range of balloons was needed for serial balloon interrogations and expansion of the landing zone stents. In this study, a checklist of the inventory of all the hardware required for the case was made, and the delivery of all the items was checked to prevent nonavailability of any of the essential consumables. This was important since PPVI is not a routinely done procedure and most of the catheterization laboratories in India, as was the case in all the four centers, do not have on shelf availability of the wide spectrum of consumables required to do these procedures safely and effectively.

Preparing the landing zone

Fear of conduit rupture

The most important step in PPVI was preparation of the landing zone or prestenting. In noncalcified conduits or bioprosthetic valves, coronary interrogation is safe even with high-pressure balloons.[13] Assessment of the coronary artery relationship with the conduit when it is heavily calcified is challenging as interrogation with semicompliant balloon may risk conduit rupture. In one of the patients who had undergone Rastelli surgery for transposition of great arteries, CECT identified left anterior descending coronary artery arising from right coronary artery crossing just below the conduit. As this conduit was heavily calcified, a covered stent was partially deployed initially and followed by serial balloon dilatation with coronary interrogation after each increment. Conduit rupture was also carefully assessed in all patients by repeated angiography following each increment of inflation during interrogation as well as stent deployment.

Coronary compression

A systematic plan helped in avoiding coronary compression in our patients. One patient with left and right coronary artery origin very close to the proximal conduit showed an uninterrupted left coronary flow during a 20 mm balloon interrogation but developed extrinsic compression of left coronary ostium due to a shift of calcium from the wall of the conduit following the use of a larger 22 mm balloon. This resulted in a careful guarded choice of 20 mm prestent and a valve with a 20 mm Ensemble delivery system. After Melody valve deployment, the gradient reduced to 10 mmHg and there were normal coronary flows. Coronary compression is the most frequent exclusion criterion and the most common cause of procedure-related deaths.[20]

Importance of optimal hemodynamic results

Hemodynamic results are crucial as gradients <10 mmHg across the landing zone produce an ideal substrate for Melody valve and delays its degeneration.[21] All the 15 patients had a landing zone gradient of ≤10 mmHg. One out of 15 patients needed a second stent proximal to the first to relieve the stenosis. Additional stents are needed in longer conduit stenosis, recoil of first stent, or asymmetric oval expansion of the stent identified on a “barrel” view from a caudal projection. Smaller prestents <18 mm diameters are not ideal, as they do not provide adequate long-term hemodynamic results. A 20 mm Ensemble system was used in 8 patients and 22 mm in seven patients, which ensured good-sized prosthesis from the point of view of long-term outcomes. In one patient with branch pulmonary artery stenosis, minimal gradients after high-pressure balloon dilatation were accepted as stents had a potential to protrude into the distal conduit thereby compromising the placement of landing zone stent. In two patients with significant pulmonary artery stenosis, stent angioplasty was performed before Melody valve implantation.


The major complications such as valve embolization, conduit rupture, or coronary compression can be life-threatening and therefore need minute attention and meticulous planning.[20],[21],[22],[23] Proper patient selection in terms of conduit/bioprosthetic valve size, generous use of covered stents for preparation of the landing zone, and frequent coronary artery injections during deployment and dilatation of the prestent helped in preventing these complications in this study. However, in rare instances when the balloon interrogation shows a pliable conduit that can be dilated to the target diameter of 20–22 mm, one-step crimping of a bare-stent around the Melody valve within the Ensemble delivery system can simplify the procedure as was done in two patients.[15] The four minor complications noted in our group were nondisabling and self-limiting and did not need any prolonged treatment. Late complications include stent fracture and endocarditis.[24] Stent fractures are reduced by preparation of the landing zone by prestenting which was done in all the patients.[25] Preimplant screening for dental and skin infections and postimplant continued counseling of patients during each follow-up visit, as was done in this study, was crucial to reduce incidence of endocarditis.[26] Furthermore, the follow-up of this cohort is too short to draw any definitive conclusions about Melody stent fractures and incidence of infective endocarditis.

Problems faced in initiating a percutaneous pulmonary valve implantation program and economics

Preimplantation training to the clinicians and observation of live cases using Melody TPV before initiating the program was certainly useful. Having a proctor with good training skills was equally essential to avoid early hiccups. These definitely helped in initiating successful programs in multiple centers as evident from our early results. One of the major reasons for the delay in initiating PPVI programs in India was the cost consideration. Significant support from charities and institutional concessions were vital to initiate and more importantly sustain such a program. The average cost of a Melody PPVI is Rs. 1,800,000 and is more than twice the cost for a surgical pulmonary valve implantation. During the initial part of this experience, a special import license was necessary from the regulatory authorities on a case-to-case basis, which contributed to additional administrative burden. Fortunately, Melody TPV got approval for use and distribution within India in the past 6 months thereby making the process of valve acquisition much simpler and easier.

   Conclusions Top

Our early experience shows encouraging results of the PPVI program in India with appropriate case selection and meticulous planning of hardware. The results confirm the safety and efficacy of Melody TPV for treating dysfunctional RVOT in repaired heart defects. Proper training and good proctoring are vital to start the program. High procedural costs may be a deterrent to economically weaker sections, and they will need financial aid and concessions. With these caveats, the procedure is applicable for selected dysfunctional RVOTs.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.

   References Top

Göber V, Berdat P, Pavlovic M, Pfammatter JP, Carrel TP. Adverse mid-term outcome following RVOT reconstruction using the Contegra valved bovine jugular vein. Ann Thorac Surg 2005;79:625-31.  Back to cited text no. 1
Bonhoeffer P, Boudjemline Y, Saliba Z, Merckx J, Aggoun Y, Bonnet D, et al. Percutaneous replacement of pulmonary valve in a right-ventricle to pulmonary-artery prosthetic conduit with valve dysfunction. Lancet 2000;356:1403-5.  Back to cited text no. 2
Cheatham JP, Hellenbrand WE, Zahn EM, Jones TK, Berman DP, Vincent JA, et al. Clinical and hemodynamic outcomes up to 7 years after transcatheter pulmonary valve replacement in the US melody valve investigational device exemption trial. Circulation 2015;131:1960-70.  Back to cited text no. 3
Fraisse A, Aldebert P, Malekzadeh-Milani S, Thambo JB, Piéchaud JF, Aucoururier P, et al. Melody ® transcatheter pulmonary valve implantation: Results from a French registry. Arch Cardiovasc Dis 2014;107:607-14.  Back to cited text no. 4
Butera G, Milanesi O, Spadoni I, Piazza L, Donti A, Ricci C, et al. Melody transcatheter pulmonary valve implantation. Results from the registry of the Italian Society of Pediatric Cardiology. Catheter Cardiovasc Interv 2013;81:310-6.  Back to cited text no. 5
Zahn EM, Hellenbrand WE, Lock JE, McElhinney DB. Implantation of the melody transcatheter pulmonary valve in patients with a dysfunctional right ventricular outflow tract conduit early results from the U.S. Clinical trial. J Am Coll Cardiol 2009;54:1722-9.  Back to cited text no. 6
Eicken A, Ewert P, Hager A, Peters B, Fratz S, Kuehne T, et al. Percutaneous pulmonary valve implantation: Two-centre experience with more than 100 patients. Eur Heart J 2011;32:1260-5.  Back to cited text no. 7
McElhinney DB, Hellenbrand WE, Zahn EM, Jones TK, Cheatham JP, Lock JE, et al. Short- and medium-term outcomes after transcatheter pulmonary valve placement in the expanded multicenter US melody valve trial. Circulation 2010;122:507-16.  Back to cited text no. 8
Warnes CA, Williams RG, Bashore TM, Child JS, Connolly HM, Dearani JA, et al. ACC/AHA 2008 Guidelines for the Management of Adults with Congenital Heart Disease: Executive Summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation 2008;118:2395-451.  Back to cited text no. 9
Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, et al. ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J 2010;31:2915-57.  Back to cited text no. 10
Silversides CK, Kiess M, Beauchesne L, Bradley T, Connelly M, Niwa K, et al. Canadian Cardiovascular Society 2009 Consensus Conference on the management of adults with congenital heart disease: Outflow tract obstruction, coarctation of the aorta, tetralogy of Fallot, Ebstein anomaly and Marfan's syndrome. Can J Cardiol 2010;26:e80-97.  Back to cited text no. 11
Geva T. Indications for pulmonary valve replacement in repaired tetralogy of fallot: The quest continues. Circulation 2013;128:1855-7.  Back to cited text no. 12
Noorani A, Radia R, Bapat V. Challenges in valve-in-valve therapy. J Thorac Dis 2015;7:1501-8.  Back to cited text no. 13
Khambadkone S. Percutaneous pulmonary valve implantation. Ann Pediatr Cardiol 2012;5:53-60.  Back to cited text no. 14
Boudjemline Y. A new one-step procedure for pulmonary valve implantation of the melody valve: Simultaneous prestenting and valve implantation. Catheter Cardiovasc Interv 2018;91:64-70.  Back to cited text no. 15
Khambadkone S, Coats L, Taylor A, Boudjemline Y, Derrick G, Tsang V, et al. Percutaneous pulmonary valve implantation in humans: Results in 59 consecutive patients. Circulation 2005;112:1189-97.  Back to cited text no. 16
Lurz P, Coats L, Khambadkone S, Nordmeyer J, Boudjemline Y, Schievano S, et al. Percutaneous pulmonary valve implantation: Impact of evolving technology and learning curve on clinical outcome. Circulation 2008;117:1964-72.  Back to cited text no. 17
Faza N, Kenny D, Kavinsky C, Amin Z, Heitschmidt M, Hijazi ZM. Single-center comparative outcomes of the Edwards SAPIEN and Medtronic Melody transcatheter heart valves in the pulmonary position. Catheter Cardiovasc Interv 2013;82:E535-41.  Back to cited text no. 18
Morgan GJ, Sivakumar K, Promphan W, Goreczny S, Prachasilchai P, Qureshi S. Early clinical experience with the straight design of Venus P valve in dysfunctional right ventricular outflow tracts. Cathet Cardiovasc Interv 2020;96:E653-9  Back to cited text no. 19
Morray BH, McElhinney DB, Cheatham JP, Zahn EM, Berman DP, Sullivan PM, et al. Risk of coronary artery compression among patients referred for transcatheter pulmonary valve implantation: A multicenter experience. Circ Cardiovasc Interv 2013;6:535-42.  Back to cited text no. 20
Eicken A, Ewert P, Hager A, Peters B, Fratz S, Kuehne T, et al. Percutaneous pulmonary valve implantation: Two-centre experience with more than 100 patients. Eur Heart J 2011;32:1260-5.  Back to cited text no. 21
Boudjemline Y, Malekzadeh-Milani S, Patel M, Thambo JB, Bonnet D, Iserin L, et al. Predictors and outcomes of right ventricular outflow tract conduit rupture during percutaneous pulmonary valve implantation: A multicentre study. EuroIntervention 2016;11:1053-62.  Back to cited text no. 22
Sridharan S, Coats L, Khambadkone S, Taylor AM, Bonhoeffer P. Images in cardiovascular medicine. Transcatheter right ventricular outflow tract intervention: The risk to the coronary circulation. Circulation 2006;113:e934-5.  Back to cited text no. 23
Cardoso R, Ansari M, Garcia D, Sandhu S, Brinster D, Piazza N. Prestenting for prevention of melody valve stent fractures: A systematic review and meta-analysis. Catheter Cardiovasc Interv 2016;87:534-9.  Back to cited text no. 24
Nordmeyer J, Lurz P, Khambadkone S, Schievano S, Jones A, McElhinney DB, et al. Pre-stenting with a bare metal stent before percutaneous pulmonary valve implantation: Acute and 1-year outcomes. Heart 2011;97:118-23.  Back to cited text no. 25
Tanase D, Ewert P, Hager A, Georgiev S, Cleuziou J, Hess J, et al. Infective endocarditis after percutaneous pulmonary valve implantation-A long-term single centre experience. Int J Cardiol 2018;265:47-51.  Back to cited text no. 26

Correspondence Address:
Dr. Kothandam Sivakumar
Institute of Cardio Vascular Diseases, Madras Medical Mission, 4A, Dr. J J Nagar, Mogappair, Chennai - 600 037, Tamil Nadu
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/apc.apc_73_21

Rights and Permissions


  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]

  [Table 1]